logo-loader
AusCann Group Holdings Ltd

AusCann Group chairman buys $58,238 worth of shares on-market

The purchase follows the recent appointment to CEO of ex Teva Pharmaceutical executive, Ido Kanyon.

three empty board seats
The chairman is one of the company's largest shareholders

AusCann Group Holdings Ltd's (ASX:AC8) chairman Mal Washer has purchased 144,000 shares in the company valued at $58,238.

The purchase was completed via on-market trades and increases Washer's total holding in the company to 12.85 million shares.

Shares in the company last traded at 38 cents, a discount to Washer's average purchase price of 40.44 cents.

READ: AusCann Group appoints Teva Pharmaceutical executive as new CEO

Recently, AusCann appointed global pharmaceutical business executive Ido Kanyon, as its CEO commencing 22 May 2019.

Kanyon brings more than 15 years’ senior executive experience in the pharmaceutical industry most recently at multi-billion dollar Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Teva is the world's largest generic pharmaceutical company which also specialised in the development and commercialisation of active pharmaceutical ingredients and specialty proprietary medicines.

Quick facts: AusCann Group Holdings Ltd

Price: $0.37

Market: ASX
Market Cap: $117.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Auscann targeting pain management with Australian cannabinoid products

Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....

on 6/9/18

2 min read